ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
U.S. Stock Futures Slip as Year-End Trading Turns Cautious 
Vietnam Central Bank Faces Challenges Meeting 2026 Economic Growth Target Amid Global Uncertainty 
Oil Prices Rise as Ukraine Peace Talks and Middle East Tensions Stir Supply Concerns 
China’s Central Bank to Launch New Digital Yuan Management Framework from January 1 
China LNG Imports Rise in December as Long-Term Contracts Drive Growth 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
BOJ Signals Further Rate Hikes as Inflation and Weak Yen Remain in Focus 
Oil Prices Slide in 2025 as Oversupply and Geopolitical Risks Shape Market Outlook 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Asian Markets Slip as Precious Metals Cool, Geopolitical Tensions Weigh on Sentiment 
Gold Prices Ease After Record Highs as Dollar Firms, Broader Bullish Outlook Intact 
China to Cut Import Tariffs on Key Commodities and Medical Products From Next Year 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Samsung Biologics is expanding its CMO or contract manufacturing organization business, and as part of its plans, it is constructing its very first overseas production plant in the United States.
On Monday, June 13, Samsung Biologics’ chief executive officer, John Rim, shared that they are considering several locations for the facility. He said that the strongest candidates for their CMO site are Texas, North Carolina, California, and Washington.
According to The Korea Herald, Samsung Biologics is looking into these places more because many of the major bio companies’ facilities are also operating in the mentioned US states. At this time, the company has not yet made any decision and carefully reviewing the areas to choose the best option.
“We are certainly expanding and the Plant 4 will begin partial operation in October, adding a 60,000-liter production capacity,” the Samsung Biologics’ CEO told the media during the press meeting for the 2022 BIO International Convention in San Diego, California. “By the second quarter of next year, it will have a 180,000-liter production capacity.”
While planning to build its first manufacturing plant abroad, Samsung Biologics has already set up its fourth factory in Songdo, Incheon, in South Korea. Once this facility starts operating at its full capacity, it is expected to boost production.
All in all, the four plants should produce 620,000 liters of products for around 30% of the global demand. It was said that Samsung Biologics’ Plant 4 currently has the biggest CMO production capacity in the world, with 256,000 liters of products in a single facility.
Rim revealed that they are also aiming to build the fifth and sixth factories in South Korea, and this is why they are buying more land in Incheon. The purchases were originally expected to be completed by the end of May, but the authorities could not sign the contract because the government officials who are in charge, which are the mayor and commissioner of the Incheon Free Economic Zone, have changed due to the local elections that was held earlier this month.
Finally, the Samsung Biologics chief said that they still plan to go ahead with the construction of Plant 5 and 6. However, they will not be monitoring the supply and demand trends to see if there is still a need to build more factories.
